Loading clinical trials...
Loading clinical trials...
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
Conditions
Interventions
spartalizumab
LAG525
+4 more
Locations
13
United States
Columbia University Medical Center- New York Presbyterian Columbia
New York, New York, United States
Sarah Cannon Research Institute Sarah Cannon Research
Nashville, Tennessee, United States
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Shatin, New Territories, Hong Kong, Hong Kong
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Milan, MI, Italy
Start Date
January 31, 2019
Primary Completion Date
February 6, 2023
Completion Date
February 6, 2023
Last Updated
May 18, 2025
NCT06547840
NCT06649331
NCT07029399
NCT06878248
NCT06189209
NCT07218003
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions